Pleyer, L., Zhang, X., Drost, M., Angermann, H., Oberlechner, J., Pfeilstöcker, M., Petzer, V., Heibl, S., Moritz, J., Girschikofsky, M., Stampfl-Mattersberger, M., Pichler, A., Hartmann, B., Aschauer, G., Schmitt, C., Vallet, S., Boros, S., Pichler, P., Hammerl-Steiner, A., Andel, J., Bewersdorf, J. P., Zeidan, A., Menezes, D. L. D., Prebet, T., Melchardt, T., Greil, R., Gaugler, L. (2025). Multivariable-adjusted validation of IWG23-defined peripheral blood complete remission (PB-CR) and IWG23 response criteria in 2,042 patients with MDS, CMML or AML treated with diverse first-line therapies: Insights from the AML-001 trial (NCT01074047) and the ‘austrian myeloid registry’ (NCT04438889) of the AGMT study group. Blood. https://doi.org/10.1182/blood-2025-3859